1-2 of 2
Gert Riethmueller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Free
Max S Topp, Gerhard Zugmaier, Nicola Goekbuget, Peter Kufer, Mariele Goebeler, Matthias Klinger, Evelyn Degenhard, Patrick A Baeuerle, Margit Schmidt, Dirk Nagorsen, Svenja Neumann, Heinz A Horst, Thorsten Raff, Andreas Viardot, Matthias Stelljes, Mathias Schmid, Oliver G. Ottmann, Thomas Burmeister, Hermann Einsele, Gert Riethmueller, Dieter Hoelzer, Ralf C Bargou
Journal: Blood
Blood (2009) 114 (22): 840.
https://doi.org/10.1182/blood.V114.22.840.840
Published: 2009
Journal Articles

The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104.

Free
Ralf C. Bargou, MD, Peter Kufer, PhD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Rudolf Noppeney, MD, Andreas Viardot, MD, Georg Hess, MD, Gert Riethmueller, PhD, Dirk Reitsma, MD, Eugen Leo, MD, Carsten Reinhardt, MD, Gerhard Zugmaier, MD
Journal: Blood
Blood (2007) 110 (11): 2557.
https://doi.org/10.1182/blood.V110.11.2557.2557
Published: 2007